Literature DB >> 25945053

Factors associated with poor discharge status in patients with status epilepticus at Khon Kaen Hospital.

Piyawan Chiewthanakul1, Parinya Noppaklao2, Kittisak Sawanyawisuth3, Somsak Tiamkao4.   

Abstract

BACKGROUND: Status epilepticus (SE) is a serious neurological condition and has high a mortality rate. Data on importance of factors associated with poor outcomes in Asian or Thai populations are limited.
METHODS: Adult patients diagnosed as SE at Khon Kaen Hospital, Thailand from October 1, 2010 to September 30, 2012 were enrolled. Patients were categorized as good or poor outcomes at discharge. Good outcomes were defined by improvement at discharge and absence of neurological deficits, while poor outcomes were defined by: not being improved at discharge; being discharged against advice; death; or presence of a neurological deficit. Clinical factors were compared between both groups.
RESULTS: During the study period, there were 211 patients diagnosed as SE. Of those, 130 patients were male (61.61%). The mean age of all patients was 53.28 years. Acute stroke was the most common cause of SE in 33 patients (15.64%). At discharge, there were 91 patients (43.13%) who had poor outcomes. Only initial plasma glucose levels were significantly associated with poor outcomes with an adjusted odds ratio of 1.012 (95% confidence interval of 1.003 and 1.021).
CONCLUSION: Initial plasma glucose is associated with poor discharge status in patients with SE.

Entities:  

Keywords:  hyperglycemia; outcomes; prognosis; risk factors

Year:  2015        PMID: 25945053      PMCID: PMC4408942          DOI: 10.2147/NDT.S76193

Source DB:  PubMed          Journal:  Neuropsychiatr Dis Treat        ISSN: 1176-6328            Impact factor:   2.570


Introduction

Status epilepticus (SE) is an emergency neurological condition defined as a continuous seizure of more than 5 minutes.1 Its prevalence varies between 10 and 41 cases per 100,000 population outside of Thailand.2 In Thailand, SE occurred in 5.10 cases per 100,000 population with a mortality rate of 0.6 per 100,000 population.3 Causes of SE are different between countries. A report from Taiwan showed that central nervous system infection and previous strokes are the two most common causes of SE,4 while antiepileptic drug (AED) withdrawal and alcohol-related causes were leading causes of SE in Western countries.5 Factors associated with poor outcomes of SE were related to comorbid complications such as metabolic disorders, cerebrovascular disease, and hypoxemia as shown in systematic reviews.6,7 A report from Thailand did not find any significant predictors for SE.2 Unlike in Western countries, there are limited data on predictors of SE outcomes in Thailand and other Asian countries. Here, the study was aimed to determine whether any factors associated with initial laboratory findings or treatment of SE had influences on outcomes at discharge.

Materials and methods

This study retrospectively reviewed charts of adult patients who were at least 15 years old and diagnosed as SE at Khon Kaen Hospital from October 1, 2010 to September 30, 2012. SE patients were identified by using the International Classification of Diseases code G41. Khon Kaen Hospital is the tertiary care hospital located in the northeastern part of Thailand. Baseline characteristics, initial laboratory findings, treatment, and treatment outcomes were recorded. Patients were categorized into two groups by type of discharge status and neurological outcomes; good or poor outcomes. Good outcomes were defined by improvement at discharge and absence of neurological deficits, while poor outcomes were defined by: not being improved at discharge; being discharged against advice; death; or presence of a neurological deficit.

Statistical analysis

Descriptive statistics were used to detect significant differences between patients with good and poor outcomes. Univariate logistic regression analysis was applied to calculate the crude odds ratios (ORs) of individual variables for having poor outcomes. All variables with P<0.20 in univariate analysis were included in subsequent multivariate logistic regression analysis. The final model was composed of factors associated with poor outcomes. Analytical results are presented as adjusted ORs, and 95% confidence intervals. The study protocol was approved by an institutional review committee, Khon Kaen University (HE 561217).

Results

During the study period, there were 211 patients diagnosed as SE. Of those, 130 patients were male (61.61%). The mean age (standard deviation [SD]) of all patients was 53.28 years (15.92). Epilepsy (24.64%) and hypertension (23.22%) were the two most common comorbid diseases. Generalized tonic–clonic seizure was the most common type of SE (179 patients; 94.71%). Acute stroke was the most common cause of SE in 33 patients (15.64%). Other common causes of SE are shown in Table 1. The mean (SD) numbers of AEDs used were 2.05 (1.56) and the mean (SD) length of stay was 5.12 days (6.75). There were 104 patients (49.29%) who developed complications after SE and the most common complication was aspiration pneumonia (53 patients; 25.12%).
Table 1

Causes of status epilepticus in the present study

CausesNumber (%)
Acute stroke33 (15.64)
Alcohol related (withdrawal/toxicity)30 (14.22)
Sepsis24 (11.37)
Central nervous system infection19 (9.00)
AED withdrawal19 (9.00)
Cardiac arrest18 (8.53)
Post-stroke11 (5.21)
Subtherapeutic AED level11 (5.21)
Hyponatremia7 (3.32)
Hyper-/hypoglycemia5 (2.37)
Acute subdural hematoma4 (1.90)
Uremia4 (1.90)
Acute febrile illness4 (1.90)
Hypertensive encephalopathy4 (1.90)
Sleep deprivation4 (1.90)
Venous sinus thrombosis3 (1.42)
Others11 (5.21)

Notes: “Others” were autoimmune encephalitis, brain abscess, hydrocephalus, central nervous system vasculitis, hypocalcemia, intracerebral hemorrhage, posterior reversible encephalopathy syndrome, subarachnoid hemorrhage, and subdural hygroma.

Abbreviation: AED, antiepileptic drug.

At discharge, there were 120 patients (56.87%) who had good outcomes, while 91 patients (43.13%) had poor outcomes categorized by: death (29 patients; 13.74%); not improved or discharged against advice (55 patients; 26.07%); and presence of neurological deficits (7 patients; 3.32%). Most clinical factors at initial presentation were comparable between those who had good and poor outcomes at discharge (Tables 2 and 3). Those who had poor outcomes had more SE occurrences in hospital (30.77% versus 3.33%), a lower Glasgow coma scale (7.97 versus 9.78), higher plasma glucose (203.11 versus 159.26 mg/dL), lower serum albumin (2.73 versus 3.52 g/dL), higher serum aspartate aminotransferase (171.36 versus 82.78 U/L), and higher total bilirubin (1.84 versus 1.04 mg/dL) than those with good outcomes. The serum electrolytes, except for potassium and phosphate levels, were also statistically different between those who had good and poor outcomes (Table 3). In the final model of multivariate analysis, only plasma glucose was significantly associated with poor outcomes with an adjusted OR of 1.012 (95% confidence interval of 1.003 and 1.021).
Table 2

Clinical factors at initial presentation of patients with SE categorized by type of hospital discharge

FactorsGood outcomeN=120Poor outcomeN=91P-value
Male76 (63.33)54 (59.39)0.555
Mean age (SD), years52.71 (18.71)54.04 (19.58)0.655
Comorbid diseases
 Hypertension28 (23.33)21 (23.08)0.965
 Diabetes mellitus23 (19.17)16 (17.58)0.769
 Alcoholism13 (10.83)7 (7.69)0.445
 Stroke27 (22.50)20 (21.98)0.928
 Epilepsy31 (25.83)21 (23.08)0.645
Causes of SE
 Acute stroke22 (18.33)11 (12.09)0.432
 AED withdrawal9 (7.50)10 (10.99)0.381
 Alcohol related14 (11.67)16 (17.58)0.223
 Cardiac arrest11 (9.17)7 (7.68)0.704
 CNS infection7 (5.83)12 (13.19)0.065
 Septic encephalopathy12 (10.00)12 (13.19)0.470
Type of SE
 Generalized tonic–clonic103 (95.37)76 (93.83)0.703
 Nonconvulsive1 (0.93)2 (2.47)0.703
 Epilepsia partialis continua4 (3.70)3 (3.70)0.703
Place of SE occurrence
 Home106 (88.33)55 (60.44)<0.001
 Primary Hospital10 (8.33)8 (8.79)<0.001
 Khon Kaen hospital4 (3.33)28 (30.77)<0.001
History of previous SE10 (8.33)2 (2.20)0.057

Notes: Poor outcome: discharge by death, not improved, or discharged against advice. Khon Kaen Hospital is a tertiary care hospital. Data presented as number (percentage) unless indicated.

Abbreviations: AED, antiepileptic drug; CNS, central nervous system; SD, standard deviation; SE, status epilepticus.

Table 3

Physical signs and laboratory findings at initial presentation of patients with status epilepticus categorized by type of hospital discharge

FactorsGood outcomeN=120Poor outcomeN=91P-value
Body temperature, °C37.22 (1.01)37.42 (1.26)0.219
Systolic blood pressure, mmHg138.22 (28.41)138.24 (32.72)0.996
Pulse rate, bpm98.42 (23.40)102.44 (24.75)0.249
Glasgow coma scale9.78 (3.51)7.97 (4.01)<0.001
Endotracheal intubation, n (%)67 (58.26)58 (65.17)0.315
Laboratory results
 Hematocrit, %26.04 (17.53)23.83 (17.76)0.367
 White blood cell count, cells/mm38,492.60 (6,724.24)8,411.43 (7,789.93)0.936
 Plasma glucose, mg/dL159.26 (84.18)203.11 (121.93)0.006
 Blood urea nitrogen, mg/dL13.32 (10.69)31.09 (36.64)<0.001
 Creatinine, mg/dL1.18 (1.26)2.01 (1.88)<0.001
 Serum sodium, mEq/L135.49 (8.03)138.03 (6.57)0.034
 Serum potassium, mEq/L3.57 (0.89)3.70 (0.77)0.318
 Serum chloride, mEq/L99.27 (9.09)103.30 (7.27)0.006
 Serum bicarbonate, mEq/L22.37 (4.81)20.03 (5.82)0.007
 Serum calcium, mg/dL8.44 (0.88)8.30 (1.38)0.532
 Serum phosphate, mg/dL3.02 (1.12)3.79 (2.27)0.037
 Total cholesterol, mg/dL168.08 (49.37)158.87 (57.92)0.555
 Serum albumin, g/dL3.52 (0.66)2.73 (0.93)<0.001
 Serum ALT, U/L533.67 (61.28)147.63 (275.02)0.052
 Serum AST, U/L82.78 (102.35)171.36 (205.69)0.031
 Total bilirubin, mg/dL1.04 (0.79)1.84 (1.49)0.017
 Alkaline phosphatase, mg/dL111.31 (81.39)106.89 (88.13)0.857

Note: Data presented as mean (standard deviation) unless indicated otherwise.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

Regarding treatment and treatment outcomes, those with poor outcomes had a higher proportion of recurrent SE (42.86% versus 10.83%) and longer duration of respirator use (4.18 versus 1.83 days) as shown in Table 4.
Table 4

Treatment and treatment outcomes of patients with SE categorized by type of hospital discharge

FactorsGood outcomeN=120Poor outcomeN=91P-value
SE time prior to treatment, minutes150.83 (257.64)159.19 (344.43)0.848
SE treatment time to control SE, minutes88.81 (175.08)191.47 (621.38)0.143
Total SE time, minutes225.77 (268.90)360.09 (723.49)0.108
Recurrent SE, n (%)13 (10.83)39 (42.86)<0.001
Interictal time, hours5.54 (12.24)1.16 (6.59)0.001
Numbers of AED use2.55 (1.71)2.44 (1.35)0.612
Types of AED use
Primary AED
 Diazepam, n (%)91 (75.83)69 (75.82)0.747
 Phenytoin, n (%)26 (21.67)21 (23.08)0.747
 Sodium valproate, n (%)3 (2.50)1 (1.10)0.747
Secondary AED
 Phenytoin, n (%)91 (98.91)77 (100)0.359
 Sodium valproate, n (%)1 (1.09)00.359
Others
 Midazolam, n (%)03 (0.03)0.079
 Propofol, n (%)02 (0.02)0.185
Length of hospital stay, days4.69 (6.12)5.69 (7.50)0.287
Duration of respirator use, days1.83 (3.92)4.18 (6.21)<0.001
Aspirated pneumonia, n (%)33 (27.50)20 (21.98)0.360

Note: Data presented as mean (standard deviation) unless indicated otherwise.

Abbreviations: AED, antiepileptic drug; SE, status epilepticus.

Discussion

This study showed two important findings: poor discharge status of SE in a tertiary care hospital was 43.13% and the discharge status of SE patients was associated with initial plasma glucose levels. An increase of 1 mg/dL of plasma glucose increased the risk of having poor discharge status by 1.2%. A previous study from Singapore also showed that in SE patients with a hyperglycemia equal to or more than 7 mmol/L (126 mg/dL), these levels were associated with poor outcomes of SE.8 In animal models, hyperglycemia causes hippocampal damage and also aggravates seizures.9,10 Therefore, glucose control may be important in SE patients, particularly in Asian populations. These results may not apply to Western populations. Two studies from Switzerland did not have findings similar to this study.11,12 Hyperglycemia was, however, shown to be associated with poor outcome in acute ischemic stroke.13 Some factors such as serum albumin or aspartate aminotransferase were significantly different between the good and poor SE outcomes by univariate logistic analysis or descriptive statistics. Both factors, however, were not statistically significant in the multivariate logistic regression analysis. These results implied that only plasma glucose was an independent factor or predictor for SE outcome. The population of this study may be different from other previous studies in terms of causes of SE. In the current study, acute stroke, alcohol related causes, and septic encephalopathy accounted for 41.23% of the entire subjects. Unlike in Western populations, AED withdrawal was found only in 9%. The previous study from Thailand found that the mortality rate of SE was 35%,2 while refractory SE may have a mortality rate of 50%.14,15 The poor outcome rate of this study was 43.13%. The poor discharge statuses were one of the following: death; not improved or discharged against advice; or presence of a neurological deficit. The strengths of this study were the quite-large sample size and different causes of SE as compared with previous studies.11,12 There are some limitations. Retrospective data collection may not have complete data, particularly laboratory findings such as HbA1c levels or history of previous medications that may affect plasma glucose levels such as steroid use. Also noted was that the population in this study was mostly not refractory SE; only three and two patients had received midazolam and propofol, respectively. Further studies are needed particularly in refractory SE. The results of this study may apply only to Asian populations or other countries in Southeast Asia.

Conclusion

Initial plasma glucose is associated with poor discharge status in patients with SE.
  15 in total

1.  Factors predictive of outcome in patients with de novo status epilepticus.

Authors:  M-H Tsai; Y-C Chuang; H-W Chang; W-N Chang; S-L Lai; C-R Huang; N-W Tsai; H-C Wang; Y-J Lin; C-H Lu
Journal:  QJM       Date:  2008-11-16

2.  Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study.

Authors:  Raoul Sutter; Stephan Marsch; Peter Fuhr; Stephan Rüegg
Journal:  Epilepsia       Date:  2013-01-07       Impact factor: 5.864

3.  Treatment deviating from guidelines does not influence status epilepticus prognosis.

Authors:  Andrea O Rossetti; Vincent Alvarez; Jean-Marie Januel; Bernard Burnand
Journal:  J Neurol       Date:  2012-08-17       Impact factor: 4.849

4.  Role of comorbidities in outcome prediction after status epilepticus.

Authors:  Vincent Alvarez; Jean-Marie Januel; Bernard Burnand; Andrea O Rossetti
Journal:  Epilepsia       Date:  2012-03-29       Impact factor: 5.864

Review 5.  Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review.

Authors:  Aidan Neligan; Simon D Shorvon
Journal:  Arch Neurol       Date:  2010-08

Review 6.  Prognostic factors, morbidity and mortality in tonic-clonic status epilepticus: a review.

Authors:  A Neligan; S D Shorvon
Journal:  Epilepsy Res       Date:  2010-10-13       Impact factor: 3.045

7.  Functional and cognitive outcome in prolonged refractory status epilepticus.

Authors:  Alex D Cooper; Jeffrey W Britton; Alejandro A Rabinstein
Journal:  Arch Neurol       Date:  2009-12

8.  Diabetic hyperglycemia aggravates seizures and status epilepticus-induced hippocampal damage.

Authors:  Chin-Wei Huang; Juei-Tang Cheng; Jing-Jane Tsai; Sheng-Nan Wu; Chao-Ching Huang
Journal:  Neurotox Res       Date:  2009-02-18       Impact factor: 3.911

9.  Status epilepticus. Causes, clinical features and consequences in 98 patients.

Authors:  M J Aminoff; R P Simon
Journal:  Am J Med       Date:  1980-11       Impact factor: 4.965

10.  A national database of incidence and treatment outcomes of status epilepticus in Thailand.

Authors:  Somsak Tiamkao; Sineenard Pranbul; Kittisak Sawanyawisuth; Kaewjai Thepsuthammarat
Journal:  Int J Neurosci       Date:  2013-10-29       Impact factor: 2.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.